anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A hair lacquer preparation comprising a homo- or co-polymer of an N-vinyl-N-(C1- 8 hydrocarbon substituted) acetamide dissolved in a quick-drying organic solvent, e.g. an alkenol, which is compatible with fluorinated hydrocarbon propellant, e.g. trichlorofluoromethane and dichloro-difluoromethane, which may also be added.  Further additives include plasticizers, e.g. dimethyl phthalate or glycerol monoricinoleate, lanolin derivatives, perfumes or dyes.ALSO:A low lacquer preparation may contain either a homopolymer of an N-vinyl-N-(C1- 8 hydrocarbon substituted) acetamide or at least one interpolymer of an N-vinyl-N-(C1- 8 hydrocarbon substituted) acetamide with at least one copolymerizable ethylenically unsaturated monomer, the polymers having an intrinsic viscosity of from 0.04 to 1.0 dl/g. in benzene at 25 DEG  C.  Exemplified copolymers are with vinyl acetate.  The hair lacquers are formulated by dissolving the polymers in a quick-drying organic liquid, e.g. an alcohol, which is compatible with fluorinated hydrocarbon propellants, e.g. trichlorofluoromethane and dichlorodifluoromethane. Other additives such as plasticizers, e.g. dimethyl phthalate or glycerol monoricinoleate, lanolin derivatives, perfumes or dyes.ALSO:A hair laquer preparation comprises a homo or copolymer of an N-vinyl-N- (C1-8 hydrocarbon substituted) acetamide dissolved in a quick drying organic solvent, e.g. an alkanol which is compatible with fluorinated hydrocarbon propellants, e.g. trichloro fluoromethane and dichloro difluoromethane, which may also be added.  Further additives include plasticizers, e.g. dimethyl phthalate or glycerol monoricinoleate, lanolin derivatives, perfumes or dyes.
In the on-going study in progress we use an extensive battery of assessments to investigate a)fasting levels of glucose and lipids at baseline and monthly during 5 months of treatment, b) glucose tolerance tests to investigate glucose and insulin abnormalities after a glucose load at baseline and during study treatment, and c)the effects of treatment with olanzapine and risperidone of post prandial glucose metabolism after a fatty meal (as detailed in the body of the proposal). Recent studies have shown that increased postprandial lipidemia is an important feature of many patients with type 2 diabetes and atherosclerosis. In addition to the biochemical measures, we will also assess clinical effects (PANSS and CGI ratings) and other side-effects (weight gain, appetite, somnolence, and EPS and TD). The specific plan calls for inpatients in a tertiary care hospital to be randomly assigned to olanzapine or risperidone, using a stratified random assignment procedure, and treated for five months with either olanzapine or risperidone. We estimate that we will have to enroll a sample of approximately 50-55 patients to obtain 46 acceptable complete cases(as specified in proposal below). On the basis of preliminary results from our prior and ongoing studies we predict no significant increase in glucose abnormalities from baseline during chronic treatment with olanzapine and no significant differences in development of glucose abnormalities in patients in patient treated with olanzapine and risperidone.

Additional measures being investigated include: comparison of olanzapine and risperidone in glucose and lipid responses to a fatty meal, ghrelin changes in response to a fatty mean, and CRP and IL-6, and thyroid and prolactin response to five months of treatment with the two drugs.
The present invention provides algin oligosaccharides having polymerized degree of 2-22 and the derivatives thereof, such algin oligosaccharides are made of mannuronic acid bonded by alpha-1,4 glycosidic bond. The derivatives which the reduced terminal in position-1 is carboxyl radical can be obtained by oxidation. The invention also provides the manufacture of algin oligosaccharides and the derivatives thereof, which includes the alginate solution in water reacts in the reactor under the condition of high press, 100-120C, pH2-6, for 2-6 hours, after the reaction completed, its pH value was adjusted to 7. The result oligosaccharides are oxidated in presence of the oxidant, and then produces the oxidated products. The algin oligosaccharides and the derivatives thereof of the invention can be used in the manufacture of medicaments for preventing Alzheimer's dementia. ® KIPO & WIPO 2007
The system and method can be used to teach individuals to quickly and easily stop incessant, repetitive thinking. Because each person is unique and has developed their own ways to deal with internal and external stimuli, the system contains tailored approaches to address the typical ways in which the general population approaches the world. Choosing a goal (typical issue) allows for targeting exercises that are designed for individualized approaches. Exercises can typically be performed very quickly (usually around 30 seconds) and can usually be completed just about anywhere. A quick check-in before and after completing an exercise allows for a quick evaluation if performing exercise worked effectively. If exercises have been effective for the individual, they can be saved for quick retrieval.
This medicine is used treat Cancer, Pain and Bipolar. It can be taken as food or as a potent medicine in therapeutic effective amounts and potencies. It treats Cancer, depression, psychosis, manic symptoms, fear, Attention deficit symptoms, illness symptoms, pain, right lip retardation and removes bumps on the necks within a week or two. It is interchangeable in the ingredients. It can be combined with Pharmaceutical drugs and ingredients. It decreases the need for narcotics, cancer drugs or mental health drugs. It is extremely strong or potent and can be made weak or make your little ADD or Bipolar kid normal. It just has a continual ability. It is very potent.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease and there is a distinct differentiation of clinical manifestations. Lupus nephritis (LN) is clinically apparent in approximately half of patients. A kidney biopsy is essential to define the kidney injury, exclude other injurious causes, and determine the histopathologic subtypes. Autoantibodies are crucial to the pathogenesis and the deposition of immune complexes in glomeruli is a hallmark of LN. The histopathology of LN is quite varied. Despite pauci-immune LN being an unexpected condition in SLE, it has been observed rarely with the presence of antineutrophil cytoplasmic autoantibodies (ANCA). We present a young male who was admitted to the emergency with syncope. The brain imaging revealed small infarct areas and signs of cerebral vasculitis. Also, he had elevated inflammatory markers, moderate proteinuria, and preserved kidney function. Anti-nuclear antibodies and anti-dsDNA were positive. Pauci-immune crescentic glomerulonephritis (PICGN) was observed in a kidney biopsy, however, ANCA was negative. SLE diagnosis was established by neurological manifestation, specific antibodies, proteinuria, and kidney biopsy findings. We administered a combination induction regimen, including pulse steroid and parenteral cyclophosphamide. The proteinuria was resolved in the follow-up. Our case highlights that SLE-associated ANCA-negative PICGN can be the initial presentation in the absence of typical manifestations. LN exhibits various pathological mechanisms in the kidney. As a consequence, SLE should be considered in the differential diagnosis of all forms of kidney injury.
Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodeficiency virus epitope such as an antigen, as well as methods  and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinants can be NYVAC or ALVAC recombinants. The DNA can encode at least one of: Env, Gag, Pol, or combinations thereof such as Gag and Pol or protease or Env, Gag and Pol or protease. The recombinants and gene products therefrom and antibodies generated by them have several preventive, therapeutic and diagnostic uses. DNA from the recombinants are useful as probes or, for generating PCR primers or for immunization. The immunogenicity and protective efficacy of immunization protocols involving ALVAC-FIV and priming with a recombinant canarypox virus ALVAC-FIV followed by a booster immunization with inactivated FIV-infected celled vaccine (ICV) was evaluated against FIV challenge in cats and the protocol was shown to effectively induce FIV-specific protective immune responses. Further, it was found that immunized cats were fully protected from an initial challenge with a slightly heterologous FIV strain (50CID50) and were partially protected from a second challenge with a distinctly heterologous FIV strain (75CID50) given eight months after the initial challenge without any intervening booster.
All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Each mL of Oral Solution for oral administration contains: 

Furosemide, USP.....................................10 mg per mL

Alcohol ....................................................11.6%

Furosemide is a diuretic which is an anthranilic acid derivative. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to off-white, odorless, crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids. The CAS Registry Number is 54-31-9. The structural formula is as follows:

Furosemide Oral Solution, USP is available for oral administration containing 10 mg per mL. The oral solution contains the following inactive ingredients: Dehydrated alcohol, D&C Yellow No. 10, FD&C Yellow No. 6, glycerin, hydrochloric acid, natural and artificial orange juice flavor, purified water, sodium hydroxide and sorbitol solution. It may contain 10% hydrochloric acid solution or 10% sodium hydroxide solution for pH adjustment. The pH range is between 7.0 and 9.0.
Intrapartum infection with group B streptococci (GBS) may lead to untoward neonatal sequelae such as pneumonia, septicemia, and meningitis. Several clinical trials have demonstrated that the use of intrapartum intravenous antibiotic prophylaxis (with penicillin being the agent of choice due to a narrower spectrum of antimicrobial activity) is highly effective to prevent early-onset neonatal GBS infections. It has been estimated that 10% to 30% of all pregnant women are GBS carriers, and it is likely that GBS colonizes virtually every female at some point. Consensus guidelines from the Centers for Disease Control and Prevention (CDC), American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics, recommend prenatal screening at 35 to 37 weeks of gestation and chemoprophylaxis at delivery based upon this culture result. The CDC-recommended method for detecting GBS colonization involves collecting a combined vaginal and rectal specimen and culturing the organism in a selective broth medium, followed be subculturing onto blood agar plates.

However, this traditional method of culture takes up to 72 hours for results to be available. With 12.8% of patients experiencing a preterm delivery prior to when a GBS screening occurs, and up to 15% of term pregnancies not having routine GBS screening performed, a significant portion of women present with unknown GBS status at the time of potential delivery. These clinical situations require obstetricians to utilize a risk-based strategy that has been shown to be only half as effective as culture-based screening. Thus, a need exists for a rapid detection method for GBS.

Recent research has focused on polymerase chain reaction (PCR) based methods for detection of GBS. Sensitivity for detection of GBS by the PCR assay has ranged from 87% to 91%. These methods are limited by high cost, and inability to perform antibiotic sensitivities for GBS (in women with a penicillin allergy). New technologies, called bionanopore (BNP) and bionanofilter (BNF) are rapid, microbial detection systems that utilizes sandwiched-membrane petri technology. These have the advantage of detecting GBS in less than 6 hours, with less cost, and the potential of allowing antibiotic sensitivities to be performed.
Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
Pantries assigned to the intervention group will receive behavioral nudges for implementing the SWAP nutrition program. These include: 1) invoice labeling with the food labeled as red, yellow, or green; 2) receipt of the SWAP toolkit at no cost; 3) pantry learning communities; 4)incentives to purchase SWAP implementation materials (e.g., shelves); 5) food bank recognition for SWAP implementation.
BACKGROUND: Due to their resistance and difficulty in treatment, biofilm-associated infections are problematic among hospitalized patients globally and account for 60% of all bacterial infections in humans. Antibiofilm peptides have recently emerged as an alternative treatment since they can be effectively designed and exert a different mode of biofilm inhibition and eradication.
METHODS: A novel antibiofilm peptide, BiF, was designed from the conserved sequence of 18 α-helical antibiofilm peptides by template-assisted technique and its activity was improved by hybridization with a lipid binding motif (KILRR). Novel antibiofilm peptide derivatives were modified by substituting hydrophobic amino acids at positions 5 or 7, and both, with positively charged lysines (L5K, L7K). These peptide derivatives were tested for antibiofilm and antimicrobial activities against biofilm-forming Staphylococcus epidermidis and multiple other microbes using crystal violet and broth microdilution assays, respectively. To assess their impact on mammalian cells, the toxicity of peptides was determined through hemolysis and cytotoxicity assays. The stability of candidate peptide, BiF2_5K7K, was assessed in human serum and its secondary structure in bacterial membrane-like environments was analyzed using circular dichroism. The action of BiF2_5K7K on planktonic S. epidermidis and its effect on biofilm cell viability were assessed via viable counting assays. Its biofilm inhibition mechanism was investigated through confocal laser scanning microscopy and transcription analysis. Additionally, its ability to eradicate mature biofilms was examined using colony counting. Finally, a preliminary evaluation involved coating a catheter with BiF2_5K7K to assess its preventive efficacy against S. epidermidis biofilm formation on the catheter and its surrounding area.
RESULTS: BiF2_5K7K, the modified antibiofilm peptide, exhibited dose-dependent antibiofilm activity against S. epidermidis. It inhibited biofilm formation at subinhibitory concentrations by altering S. epidermidis extracellular polysaccharide production and quorum-sensing gene expression. Additionally, it exhibited broad-spectrum antimicrobial activity and no significant hemolysis or toxicity against mammalian cell lines was observed. Its activity is retained when exposed to human serum. In bacterial membrane-like environments, this peptide formed an α-helix amphipathic structure. Within 4 h, a reduction in the number of S. epidermidis colonies was observed, demonstrating the fast action of this peptide. As a preliminary test, a BiF2_5K7K-coated catheter was able to prevent the development of S. epidermidis biofilm both on the catheter surface and in its surrounding area.
CONCLUSIONS: Due to the safety and effectiveness of BiF2_5K7K, we suggest that this peptide be further developed to combat biofilm infections, particularly those of biofilm-forming S. epidermidis.
Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
A system and method for managing healthcare information is disclosed. The data servers each include a data manager that comprises a controller, a grid engine, applications, an application manager and a user interface engine. The controller manages the core functions and the transmission of data between data manager components. The grid engine manages information sent between data servers. The applications are applications that are created by the user or downloaded as third-party applications. The application manager manages the creation and communication between applications. The user interface engine generates user interfaces for displaying the applications and collecting clinical trial data.
This invention relates to methods and reagents for inhibiting furin endoprotease activity and specifically for inhibiting furin endoprotease-mediated maturation of bioactive proteins in vivo and in vitro. The invention specifically provides proteins capable of inhibiting furin endoprotease activity. Particularly provided are α 1  -antitrypsin variants that specifically inhibit furin endoprotease activity. Methods for using furin endoprotease inhibition to attenuate or prevent viral protein maturation, and thereby alleviate viral infections, are provided. Also provided are methods for using furin endoprotease inhibition to attenuate or prevent proteolytic processing of bacterial toxins, thereby alleviating bacterial infections. Methods are also provided to inhibit proteolytic processing of biologically active proteins and peptides. The invention also provides pharmaceutically acceptable compositions of therapeutically effective amounts of furin endoprotease inhibitors.
The described implementations relate to an access control framework for a database system. One implementation can receive, from a user, a request for data that identifies a resource, such as a view that obtains data from a database. The implementation can check the identity of the user to identify user roles associated with the user. The implementation can identify an access policy that is associated with the resource, and a rule that is associated with the access policy and applies to the user roles associated with the user. The rule can be applied to the request for data using attributes of the access policy. For example, if the request for data is a query on a view, the query can be rewritten to apply the rule.
An improved process for the purification and inactivation of HBsAg from plasma from carriers of hepatitis B virus is described. This material can be employed as vaccine against this virus. The purification process consists of a fractional precipitation with polyethylene glycol, of a zonal flotation by dense salt solutions and of a final gel chromatography. The optimised sequence of these steps permits the HBsAg to be concentrated 5000-fold in 99% purity with a 95% protein yield and 60% activity yield. The use of enzymes, detergents or denaturing agents is avoided thereby. Hepatitis B viruses are attenuated by a factor of 10<4> or more. Any residual infectiosity is eliminated more reliably than hitherto with formalin in the high concentration of 1:450. The HBsAg is adsorbed directly after the inactivation on aluminium hydroxide gel, and the formalin is removed by washing the gel. The resulting suspension of HBsAg-containing gel is a vaccine which is ready for use and whose activity is higher than that of a reference material.
NEW MATERIAL:A compound expressed by formula I [X represents formula II (R2 represents H, lower alkyl, lower alkenyl, aryl, group expressed by formula III, etc.); R1 and R3 represent H, lower alkyl, cycloalkyl, lower alkenyl, aryl, etc.; R4 represents the same species as R1 or group expressed by formula IV]. USE:An antitumor agent. PREPARATION:For example, methyl iodide is added to a suspended solution of DC-45A2 and silver oxide in acetone and stirred for 5.5hr at room temperature, followed by filtration, concentration under reduced pressure and separation with silica-gel chromatography. Then each fraction corresponding to the Rf value developed by silica-gel chromatography is concentrated under reduced pressure and each concentrate is purified again with the silica-gel chromatography. The purified product is crystallized in acetone-ether to afford the compound expressed by formula I.
Equipment for carrying out cardiac autonomic neuropathy tests includes a base unit to which a mouthpiece is connected, forming an autonomous system for measuring the pressure and/or the pattern of breath, provided with a series of LEDs aimed at informing a patient, who is undergoing the test, about correctness or incorrectness of a test execution. The mouthpiece is provided with a flow sensor, aimed at measuring a patient's pattern of breath, and a pressure sensor. The mouthpiece includes also an atmospheric pressure sensor aimed at measuring the environmental pressure. The equipment includes also a sensor, aimed at measuring the heartbeat, applied by simple contact to the patient's wrist area, and an orthostatic measuring device aimed at measuring any change of the patient's position. Data can be introduced or analysed and the type of exam to do can be selected. Results of the tests can be stored in a memory.
All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
The method assesses the effectiveness of compounds for treatment of conditions characterised by a deficiency in number or function of membrane bound receptors and may be concerned with assessing putative agents for treatment of cognitive dysfunction conditions, including Alzheimer's disease. In the method, cells transfected with appropriate DNA are grown beyond the usual level to approach or reach equilibrium; the growth medium is then removed and the test agent added. A control is carried out using only the vehicle in which the test agent is dissolved. The samples are then incubated for, preferably, 72 hours, and an assay for the receptor or receptor type of interest is carried out. Comparison of results between control and test sample indicate the likely usefulness of the test compound. In a preferred embodiment, Chinese Hamster Ovary (CHO) cells are transfected with DNA for the muscarinic acetylcholine receptor, and receptor number is assayed using a [<SP>3</SP>H]-NMS and [<SP>3</SP>H]-QNB binding assay.